Acute lymphoblastic leukaemia: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD19 121
• CD22 32
• ABL1 10
• KMT2A 8
• CD20 8
• TP53 0
• AKT 0
• BCL-2 3
• PI3K 0
• CD123 5
• JAK 2
• CD38 4
• PD-1 3
• RUNX1 0
• mTOR 0
• NPM1 4
• BCMA 4
• NOTCH1 0
• CXCR4 1
• PTEN 0
• CTNNB1 0
• EGFR 0
• HDAC 0
• IDH 0
• MYC 0
• RAS 0
• STAT3 0
• AMPK 0
• CD30 0
• CD40 0
• CD47 0
• ERK 0
• FGFR 0
• MAPK 0
• MDM2 0
• PD-L1 0
• CD33 1
• FLT3 0
• IL-1 0
• IL-17 0
• IL-6 0
• KRAS 0
• MEK 0
• PPAR 0
• RANKL 0
• RB1 0
• TYK2 0
• ALK 0
• AXL 0
• BRCA1 0
• BRD4 0
• BTK 0
• CDK4/6 0
• CDKN2A 0
• CTLA-4 0
• EZH2 0
• FAK 0
• FTO 0
• GPRC5D 1
• GPX4 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 46+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

  NCT05410041· Beijing Boren Hospital· Updated 15 Oct 2026

  “No participants.”Registry text, quoted unchanged. Source

• Terminated

  A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia

  NCT07556757· ImmunityBio, Inc.· Updated 19 Aug 2026

  “Study was terminated prematurely by the Sponsor for reasons not related to the safety of study drug”Registry text, quoted unchanged. Source

• Suspended

  Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

  NCT06447987· City of Hope Medical Center· Updated 5 Jun 2026

  “Pending Interim Analysis”Registry text, quoted unchanged. Source

• Suspended

  Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL

  NCT06985498· The First Affiliated Hospital of Soochow University· Updated 29 May 2026

  “According to the new regulations of China, newly launched clinical trials involved CAR-T cells must be apporved first by China National Center for Biotechology Development.”Registry text, quoted unchanged. Source

• Terminated

  CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL

  NCT04049383· Medical College of Wisconsin· Updated 12 Jan 2026

  “Low accrual”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)

  NCT06009107· Juventas Cell Therapy Ltd.· Updated 8 Aug 2025

  “Sponsor changed product development plan”Registry text, quoted unchanged. Source

• Withdrawn

  TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant

  NCT05968170· Neena Kapoor, M.D.· Updated 14 Jul 2025

  “No funding available.”Registry text, quoted unchanged. Source

• Terminated

  A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

  NCT05292898· Institute of Hematology & Blood Diseases Hospital, China· Updated 3 Jun 2025

  “Achieve the proof of concept”Registry text, quoted unchanged. Source

• Terminated

  First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies

  NCT05348889· Chimagen Biosciences, Ltd· Updated 13 Feb 2025

  “Sponsor's Research and Development strategy adjustment”Registry text, quoted unchanged. Source

• Withdrawn

  Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT

  NCT03939585· Leland Metheny· Updated 5 Dec 2024

  “Lack of funding”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

  NCT07570173· Merck Sharp & Dohme LLC· Source

• Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

  NCT03226704· National Cancer Institute (NCI)· Source

• Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

  NCT04512716· Memorial Sloan Kettering Cancer Center· Source

• CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

  NCT05442515· National Cancer Institute (NCI)· Source

• CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL

  NCT05440409· National Cancer Institute (NCI)· Source

• CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study

  NCT07890025· Hospital Universitario Dr. Jose E. Gonzalez· Source

• Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

  NCT06364423· National Cancer Institute (NCI)· Source

• This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

  NCT07162571· Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology· Source

• Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

  NCT04732845· Benjamin Tomlinson· Source

• CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL

  NCT05470777· The First Affiliated Hospital of Soochow University· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 4
• CRISPR-Cas Systems 5
• Gene Expression Profiling 27
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 7
• Metabolomics 4
• Flow Cytometry 40
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 50
• Magnetic Resonance Imaging 14
• Machine Learning 11
• Deep Learning 8
• Cohort Studies 26
• Genome-Wide Association Study 8

• Unveiling Cerebrospinal Fluid Protein Biomarkers in Pediatric Acute Lymphoblastic Leukemia Using a Proximity Extension Assay.

  J Proteome Res, Nov 2026

• Metabolomic Profiling and Machine Learning-Based Prediction of High-Dose Methotrexate-Induced Liver Injury in Pediatric Acute Lymphoblastic Leukemia.

  Pediatr Blood Cancer, Jul 2026

• clinTALL: machine learning-driven multimodal subtype classification and treatment outcome prediction in pediatric T-ALL.

  Genome Med, Jul 2026

• Machine learning model based on clinical and imaging features for predicting fungal infections in children with leukemia.

  BMC Pediatr, Jun 2026

• A systematic review of machine and deep learning techniques for acute lymphoblastic leukemia diagnosis.

  Artif Intell Med, Mar 2026

• μPharma: A microfluidic, AI-driven pharmacotyping platform for single-cell drug sensitivity prediction in leukemia.

  Med, Jan 2026

• PREPARE ALL: An Artificial Intelligence Tool for Predicting Relapse in Children With Acute Lymphoblastic Leukemia.

  JCO Clin Cancer Inform, Jan 2026

• Efficient convolutional neural networks for acute lymphoblastic leukaemia prediction in computer vision.

  Sci Rep, Dec 2025

• A personalized communication efficient federated learning framework with low rank adaptation for intelligent leukemia diagnosis.

  Sci Rep, Dec 2025

• Pathway-Informed Machine Learning Identifies Genetic Predictors of High-Dose Methotrexate-Induced Mucositis in Pediatric Acute Lymphoblastic Leukemia.

  Clin Pharmacol Ther, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.